Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.705 USD | -0.13% | +1.63% | +22.30% |
Sales 2024 * | - | Sales 2025 * | 40.87M 3.26B | Capitalization | 312M 24.95B |
---|---|---|---|---|---|
Net income 2024 * | -231M -18.45B | Net income 2025 * | -246M -19.65B | EV / Sales 2024 * | - |
Net cash position 2024 * | 543M 43.36B | Net cash position 2025 * | 448M 35.82B | EV / Sales 2025 * | -3.33 x |
P/E ratio 2024 * |
-1.34
x | P/E ratio 2025 * |
-1.27
x | Employees | 75 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.54% |
Latest transcript on Atea Pharmaceuticals, Inc.
1 day | +0.13% | ||
1 week | +1.63% | ||
Current month | -7.67% | ||
1 month | -6.75% | ||
3 months | -5.09% | ||
6 months | +20.32% | ||
Current year | +22.30% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 68 | 30/11/12 | |
Andrea Corcoran
DFI | Director of Finance/CFO | 61 | 30/11/13 |
Maria Horga
CTO | Chief Tech/Sci/R&D Officer | 55 | 31/07/20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Franklin Berger
BRD | Director/Board Member | 74 | 31/08/19 |
Barbara Duncan
BRD | Director/Board Member | 59 | 30/09/20 |
Chief Executive Officer | 68 | 30/11/12 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 3.73 | +0.54% | 10 372 |
26/04/24 | 3.71 | +0.54% | 143,066 |
25/04/24 | 3.69 | -0.27% | 174,652 |
24/04/24 | 3.7 | -0.80% | 196,517 |
23/04/24 | 3.73 | +1.63% | 180,547 |
Delayed Quote Nasdaq, April 29, 2024 at 02:35 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+22.30% | 312M | |
-1.86% | 103B | |
+1.89% | 95.28B | |
+1.86% | 22.15B | |
-16.46% | 21.02B | |
-8.68% | 18.15B | |
-41.01% | 16.73B | |
-13.51% | 16.05B | |
+3.97% | 13.68B | |
+34.09% | 12.17B |
- Stock Market
- Equities
- AVIR Stock